TIDMSCLP
RNS Number : 9322E
Scancell Holdings Plc
15 February 2018
ISA Pharmaceuticals and Scancell enter collaboration agreement
for the manufacturing, development and commercialisation of Modi-1
/ AMPLIVANT(R) combination
AMPLIVANT-Modi-1 conjugate expected to enter clinic in H1
2019
Collaboration seeks to further leverage Moditope(R) platform
Leiden, The Netherlands, and Oxford, UK, 15 February, 2018 --
ISA Pharmaceuticals B.V. ('ISA'), a clinical-stage immunotherapy
company, and Scancell Holdings plc, ('Scancell' or the 'Company'),
the developer of novel immunotherapies for the treatment of cancer,
are pleased to announce that they have entered into a worldwide
licensing and collaboration agreement to use ISA's AMPLIVANT(R)
adjuvant technology for the manufacturing, development and
commercialisation of Scancell's first Moditope(R) development
candidate, Modi-1. This partnership has the potential to provide a
new treatment option for patients with triple negative breast
cancer, ovarian cancer, sarcomas, and other solid tumours.
Under the terms of this agreement, ISA has granted Scancell an
exclusive worldwide license to manufacture, develop and
commercialise the AMPLIVANT(R) :Modi-1 conjugate therapy and will
contribute know-how and expertise related to AMPLIVANT(R) .
Clinical studies will be conducted by Scancell and are expected to
commence in H1 2019.
In return, ISA will receive an upfront payment from Scancell and
is entitled to milestone and royalty fees following achievement of
certain criteria as defined in the agreement. Financial details
were not disclosed.
Previous pre-clinical data demonstrated that conjugation of the
Modi-1 peptides to AMPLIVANT(R) enhances anti-tumour immune
responses 10-100 fold and resulted in highly efficient tumour
eradication, including protection against tumour re-challenge.
ISA's AMPLIVANT(R) technology can be applied to any type of
targeted immunotherapy, significantly enhancing its efficacy. It is
based on a proprietary and synthetic small molecule TLR1/2 ligand
with enhanced immunostimulatory activity that can be chemically
coupled to the respective immunotherapeutic. AMPLIVANT(R)
conjugates allow lower dosing with higher efficacy through better
dendritic cell antigen processing and presentation, as well as
enhanced T cell priming.
Scancell's Moditope(R) platform acts by stimulating the
production of CD4+ T cells using citrullinated tumour-associated
peptide epitopes. This technology overcomes the immune suppression
induced by tumours themselves, allowing activated T cells to seek
out and kill tumour cells that would otherwise be hidden from the
immune system.
"This collaboration is an important step to advance new adjuvant
technologies such as AMPLIVANT(R) to clinical-stage programmes and
bring patients better treatments," said Ronald Loggers, CEO of ISA
Pharmaceuticals. "The partnership will further validate the power
of AMPLIVANT(R) conjugates for use in therapeutic cancer vaccines
that carry a variety of epitopes, including post-translationally
modified epitopes such as Scancell's Moditope(R) products."
Cliff Holloway, CEO of Scancell, commented: "This collaboration
with ISA Pharmaceuticals is an important step in the continued
development and commercialisation of our first Moditope(R)
immunotherapy, Modi-1, which has the potential to treat patients
with triple negative breast cancer, ovarian cancer and sarcoma who
are resistant to other immunotherapies. Our pre-clinical studies
have demonstrated Modi-1 induces potent anti-tumour responses and
significant improvements in survival. We believe that combining
Modi-1 with an enabling adjuvant technology such as AMPLIVANT(R)
has the potential to significantly enhance its efficacy in patients
and we are looking forward to moving this important and novel
therapy into the clinic in the first half of 2019."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR).
For Further Information:
ISA Pharmaceuticals
Dr. Ludger Wess/Ines-Regina akampion +49 40 88 16 59
Buth Managing Partners 64
+49 30 23 63 27
68
info(at)akampion.com
Scancell
Scancell Holdings
Dr John Chiplin, Chairman Plc +1 858 361 6288
Dr Cliff Holloway, CEO
Freddy Crossley (Corporate
Finance) Panmure Gordon &
Tom Salvesen (Corporate Broking) Co +44 (0) 20 7886 2500
Mo Noonan/Simon Conway FTI Consulting +44 (0) 20 3727 1000
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing
rationally designed, fully synthetic immunotherapeutics against
cancer and persistent viral infections. The company has built a
proprietary immunotherapy platform based on the Synthetic Long
Peptide (SLP(R) ) concept and AMPLIVANT(R) technology. SLP(R)
immunotherapies are designed to fully harness and direct the body's
own defenses towards fighting the disease. In December 2017, ISA
Pharmaceuticals closed a clinical immuno-oncology collaboration
with Regeneron to advance its SLP(R) lead compound ISA101, an
immunotherapy targeting human papillomavirus type 16
(HPV16)-induced cancer, in combination with cemiplimab (REGN2810),
a PD-1 (programmed cell death protein 1) antibody. In addition, ISA
develops MyISA(R) , a personalized SLP(R) immunotherapy, targeting
tumor-specific, mutation-derived neo-antigens.
For more information, please visit www.isa-pharma.com.
SLP(R) , AMPLIVANT(R) and MyISA(R) are registered trademarks in
Europe.
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
Scancell's first ImmunoBody(R), SCIB1 is being developed for the
treatment of melanoma. Data from the Phase 1/2 clinical trial
demonstrate that SCIB1, when used as monotherapy, has a marked
effect on tumour load, produces a melanoma-specific immune response
and highly encouraging survival trend without serious side effects.
In patients with resected disease there is increasing evidence to
suggest that SCIB1 may delay or prevent disease recurrence.
Scancell's ImmunoBody(R) vaccines target dendritic cells and
stimulate both parts of the cellular immune system: the helper cell
system where inflammation is stimulated at the tumour site and the
cytotoxic T-lymphocyte or CTL response where immune system cells
are primed to recognise and kill specific cells.
Pre-clinical data on a combination of SCIB1 or SCIB2 and
checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune
checkpoint pathways) have shown enhanced tumour destruction and
significantly longer survival times than when either treatment was
used alone.
Scancell has also identified and patented a series of modified
epitopes that stimulate the production of killer CD4+ T cells that
destroy tumours with minimal toxicity. The Directors believe that
the Moditope(R) platform could play a major role in the development
of safe and effective cancer immunotherapies in the future.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUSAWRWVAUAAR
(END) Dow Jones Newswires
February 15, 2018 02:00 ET (07:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024